Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $15

Benzinga · 3d ago
Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $13 to $15.